CEO COMMENTS
Kristina Torfgård comments Q1 report 2025
“The first quarter of 2025 has been one of our most dynamic to date, marked by significant regulatory progress, promising clinical results, and the deepening of strategically important partnerships, all collectively strengthening our position. Following an in-depth analysis of the topline data for pirepemat presented during the quarter, we can confidently affirm that all of our development programs continue to make evident progress and bring us closer to our goal – to provide new, effective treatments for people living with Parkinson’s disease.
Key Milestones During the Quarter:
- Promising results from the Phase I study with IRL757 enable the next step in clinical development – a study in patients with Parkinson’s and apathy. Our strategic collaboration with MSRD/Otsuka and the Michael J. Fox Foundation plays an important role in advancing the development of IRL757.
- The regulatory progress for mesdopetam lays a strong foundation for the upcoming Phase III program and deepened discussions with potential partners.
- Study data on pirepemat show a statistically significant and clinically meaningful reduction in fall rate, linked to the plasma concentrations of the drug.
Together, these advances demonstrate that we are well on our way to realizing our vision and creating value for patients, partners and shareholders.”
LATEST REPORTS
IRLAB announces the outcome of the company’s rights issue
IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) announces today, 18 July 2025 the outcome of the rights issue of shares of series A up to approximately SEK 136 million, which the Board of Directors resolved on 24 June 2025 by virtue of the authorization from the Annual General Meeting (the “Rights Issue”). The Company has received the outcome of the Rights Issue which concludes that 18,931,197 shares, corresponding to approximately 48.7 percent of the Rights Issue, have been subscribed for with the support of subscription rights. Additionally, applications for subscription of 4,838,083 shares, corresponding to approximately 12.4 percent of the Rights Issue, have been received for subscription of shares without the support of subscription rights. In aggregate, the subscriptions with the support of subscription rights and the applications for subscription without the support of subscription rights correspond to approximately 61.1 percent of the Rights Issue. Hence, guarantee undertakings of 9,300,334 shares, corresponding to approximately 23.9 percent of the Rights Issue, will be utilized. The Rights Issue will provide the Company with proceeds of approximately SEK 115.7 million before deduction of costs related to the Rights Issue and set-off of loans. The Company’s Board of Directors has resolved, in connection with the allocation, to allow the set-off of outstanding loans.
Read More >
Presentation by Kristina Torfgård, CEO, at Aktiespararna
Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.
Read More >FINANCIAL CALENDAR
NEXT
August 27 2025
Interim Report January – June 2025